Clinical trial
COVE-5: A Phase 2, Open-label Study to Evaluate the Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris)
NCT07881952 is registered in ClinicalTrials.gov with Verrica Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- COVE-5: A Phase 2, Open-label Study to Evaluate the Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris)
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- April 30, 2027
- Enrollment
- 30 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
common warts, common warts (verruca vulgaris), human papilloma virus (hpv), warts
Lead sponsor's other trials
Verrica Pharmaceuticals Inc., most recent start first.
+4 more trials See the organization page
Similar trials
Same condition (Warts) and phase, most recent start first.
+25 more trials See the condition page